These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1906726)

  • 1. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
    Topham C; Glees J; Rawson NS; Woods EM; Coombes RC
    Br J Cancer; 1991 Jul; 64(1):179-81. PubMed ID: 1906726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
    Topham C; Glees J; Coombes RC
    Oncology; 1993 Apr; 50 Suppl 1():78-80. PubMed ID: 8483561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].
    Verhees S; Flechtner H; Queisser W; Heim ME; Fritz M; Trux F; Edler L
    Onkologie; 1990 Feb; 13(1):50-2. PubMed ID: 1692400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination of 5-fluorouracil, epirubicin and mitomycin C (FEM) on advanced gastric carcinoma.
    Itoh T; Sakata Y; Tamura Y; Furukohori N; Saitoh S; Suzuki H; Tsushima K; Munakata A; Yoshida Y; Takagi S
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1551-6. PubMed ID: 2509606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
    Bruckner HW; Kalman J; Spigelman M; Gorbaty MI; Butwell N; Storch J; McKenna A
    Oncology; 1989; 46(6):366-71. PubMed ID: 2511535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma.
    Loehrer PJ; Harry D; Chlebowski RT
    Invest New Drugs; 1994; 12(1):57-63. PubMed ID: 7960608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
    Flechtner H; Queisser W; Heim ME; Henss H; Arnold H; Fritze D; Herrmann R; Fritsch H; Fritz M; Trux FA
    Onkologie; 1987 Apr; 10(2):67-71. PubMed ID: 3108738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
    Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
    J Clin Oncol; 2002 Apr; 20(8):1996-2004. PubMed ID: 11956258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
    Queisser W; Flechtner H; Heim ME; Kabelitz K; Massner B; Edler L
    Onkologie; 1989 Oct; 12(5):202-6. PubMed ID: 2511533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
    Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
    Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
    Sternberg CN; Magill GB; Sordillo PP; Cheng EW
    Am J Clin Oncol; 1984 Oct; 7(5):529-33. PubMed ID: 6391145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with 5-FU 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU), and mitomycin (FUM) for carcinoma of the pancreas.
    Meguro S; Kuraishi Y; Ichiba K; Abe M; Yoda T; Mikouchi S
    Cancer Treat Rep; 1982 Aug; 66(8):1645-6. PubMed ID: 6955023
    [No Abstract]   [Full Text] [Related]  

  • 16. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Dalesio O; Duez N; Blijham G; Planting A; Splinter T; Weber W
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1017-8. PubMed ID: 3478197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
    Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M
    Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
    Kelsen D; Hudis C; Niedzwiecki D; Dougherty J; Casper E; Botet J; Vinciguerra V; Rosenbluth R
    Cancer; 1991 Sep; 68(5):965-9. PubMed ID: 1833042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for advanced pancreatic carcinoma].
    Yokoyama T; Shimada Y
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2338-43. PubMed ID: 1463339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
    Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
    J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.